ReviewFrontiers in immunology2019
Therapeutic Potential of Regulatory T Cells in Preeclampsia-Opportunities and Challenges.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Advances in pathogenesis of preeclampsia.Archives of gynecology and obstetrics · 2024Pooled it
- Regulatory T Cells in Pregnancy Adverse Outcomes: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Review
- Integration of single-cell sequencing and transcriptomic analysis to identify novel diagnostic biomarkers for pre-eclampsia.BMC pregnancy and childbirth · 2026Article
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Hormonal Imbalance and Gut Dysbiosis: Emerging Perspectives in Women's Health.Probiotics and antimicrobial proteins · 2026Review
- Understanding Preeclampsia: Integrating Placental Dysfunction, Immune Dysregulation and microRNA-Mediated Epigenetic Regulation.International journal of molecular sciences · 2026Review
- Systemic Immune-Inflammation Index as a Predictive Biomarker for Pre-Eclampsia.Journal of clinical medicine · 2026Review
- Peripheral Regulatory T Cells Display Dynamic Memory Subset Frequency and Inhibitory Marker Expression Across Pregnancy.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Article
- Article
- Regulatory T cells in human pregnancy: mechanisms, dysregulation, and therapeutic perspectives.Frontiers in immunology · 2026Review
- Single-cell RNA sequencing of leukocytes at the maternal-fetal interface in physiological and pathological Nodal-deficient pregnancies.Frontiers in immunology · 2026Article
- Immune Cells in Preeclampsia.International journal of molecular sciences · 2025Review
- The multifactorial role of HDAC9 at the maternal-fetal interface in the pathogenesis of preeclampsia.Clinical science (London, England : 1979) · 2025Review
- The Role of Mitochondrial Dysfunction and Oxidative Stress in Women's Reproductive Disorders: Implications for Polycystic Ovary Syndrome and Preeclampsia.International journal of molecular sciences · 2025Review
- Gut Microbiome Dysbiosis and Its Impact on Reproductive Health: Mechanisms and Clinical Applications.Metabolites · 2025Review
- The maternal-fetal interface at single-cell resolution: uncovering the cellular anatomy of the placenta and decidua.American journal of obstetrics and gynecology · 2025Review
- Article
- Identification of critical biomarkers and immune infiltration in preeclampsia through bioinformatics and machine learning methods.BMC pregnancy and childbirth · 2025Article
- A comprehensive review of the roles of T-cell immunity in preeclampsia.Frontiers in immunology · 2025Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is a central feature and is implicated as a causal factor in preeclampsia and other hypertensive disorders of pregnancy. Inflammatory mediators and leukocytes, which are elevated in peripheral blood and gestational tissues, contribute to the uterine vascular anomalies and compromised placental function that characterize particularly the severe, early onset form of disease. Regulatory T (Treg) cells are central mediators of pregnancy tolerance and direct other immune cells to counteract inflammation and promote robust placentation. Treg cells are commonly perturbed in preeclampsia, and there is evidence Treg cell insufficiency predates onset of symptoms. A causal role is implied by mouse studies showing sufficient numbers of functionally competent Treg cells must be present in the uterus from conception, to support maternal vascular adaptation and prevent later placental inflammatory pathology. Treg cells may therefore provide a tractable target for both preventative strategies and treatment interventions in preeclampsia. Steps to boost Treg cell activity require investigation and could be incorporated into pregnancy planning and preconception care. Pharmacological interventions developed to target Treg cells in autoimmune conditions warrant consideration for evaluation, utilizing rigorous clinical trial methodology, and ensuring safety is paramount. Emerging cell therapy tools involving
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.